Global monovaccine (Epstein-Barr virus) market potential, by Application (Mononucleosis, Endemic Burkitt’s lymphoma, Hodgkin’s lymphoma, Gastric carcinomas, Multiple sclerosis, and Nasopharyngeal Carcinoma) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be US$ 2.0 Bn.
Frequent research and development activities and funding by various organizations is expected to lead to the development of monovaccine in future. Currently, there is no licensed vaccine for EBV. However, various universities and organizations are taking efforts to develop novel vaccines and fulfill unmet needs. For instance, in March 2017, Cancer Research U.K. completed its phase 1b clinical trial of (Modified Vaccinia Ankara) MVA-EBNA1/LMP2 vaccine. It is being treated on nasopharyngeal cancer patients with positive Epstein-Barr virus infection. In 2017, researchers from the University of Kansas School of Engineering and School of Pharmacy analyzed the genetics of human immune responses to develop basis of an effective vaccine or drug therapy against Epstein-Barr virus or EBV, the pathogen that causes infectious mononucleosis and infects around 90% of adults worldwide. In January 2019, researchers and scientists from the German Cancer Research Center developed a new strategy for creating a vaccine that targets different EBV virus life phases and has the potential to provide effective protection against EBV infection. Hence, frequent monovaccine development efforts by various universities is expected to result in development of novel vaccines and fulfill unmet needs in the near future.
Browse 10 Market Data Tables and 10 Figures spread through 84 Pages and in-depth TOC on Global Monovaccine (Epstein - Barr virus) Market by Application (Mononucleosis, Endemic Burkitt’s lymphoma, Hodgkin’s lymphoma, Gastric carcinomas, Multiple sclerosis, and Nasopharyngeal Carcinoma) and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa)
To know the latest trends and insights prevalent in the Monovaccine (Epstein - Barr virus) market, click the link below:
Various government organizations from different regions are taking efforts for the development of novel monovaccines (Epstein - Barr virus) and gaining approval. For instance, in 2019, researchers from National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) determined how various antibodies induced by Epstein-Barr virus (EBV) block infection of cells grown in the laboratory. Researchers used this information for development of novel vaccine candidates in animals, elicited potent anti-EBV antibody responses that blocked infection of cell types involved in EBV-associated cancers.
Key Takeaways of the Global Monovaccine (Epstein-Barr virus) Market:
Joining thousands of companies around the world committed to making the Excellent Business Solutions.